Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Randall Stern

Vascular Surgery Fresno, CA Medical Doctor

NPI 1962512319 CMS profile 361160

1247 E Alluvial Ave Ste 101, Fresno, CA 93720

Open in the dashboard

General payments

$69,722

162 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Randall Stern of Fresno, CA is reported in the CMS Open Payments database as having received $69,722 across 162 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $449 4
2024 General $271 8
2023 General $900 11
2022 General $3,331 13
2021 General $7,160 34
2020 General $2,978 32
2019 General $54,633 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Randall Stern
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Randall Stern were reported at $449. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Randall Stern Vascular Surgery median Middle half National median
2019 $54,633 $796 $226–$2,363 $163
2020 $2,978 $348 $118–$1,110 $114
2021 $7,160 $471 $158–$1,421 $132
2022 $3,331 $725 $222–$2,183 $149
2023 $900 $836 $257–$2,440 $160
2024 $271 $909 $252–$2,619 $164
2025 $449 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $65,744 73 payments
  2. W. L. Gore & Associates, Inc. $1,380 6 payments
  3. Shockwave Medical, Inc $608 6 payments
  4. Abbott Laboratories $424 34 payments
  5. Medtronic Vascular, Inc. $303 6 payments
  6. Urgo Medical North America, LLC $292 9 payments
  7. Penumbra, Inc. $166 1 payment
  8. Humacyte Global, Inc. $145 1 payment
  9. PolyNovo North America LLC $133 1 payment
  10. Bolton Medical Inc $126 6 payments
  11. Other $401 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $55,860 21 payments
  2. Travel and Lodging $5,938 14 payments
  3. Food and Beverage $4,923 125 payments
  4. Consulting Fee $3,000 2 payments
Products named General payments · program years 2019–2025
  1. XARELTO $65,778 74 payments
  2. VIABAHN Endoprosthesis $729 3 payments
  3. TAG Thoracic Endoprosthesis $494 2 payments
  4. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Lithoplasty $453 4 payments
  5. VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP $229 6 payments
  6. Endurant $171 3 payments
  7. RUBY Coil $166 1 payment
  8. EXCLUDER Conformable AAA Endoprosthesis with Active Control $157 1 payment
  9. Symvess $145 1 payment
  10. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Cardiology $123 1 payment
  11. Other $1,184 67 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

92

Median for Vascular Surgery: 122

Drug cost

$64,028

Median for Vascular Surgery: $14,135

Branded share of claims

100%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 74 $63,714
Clopidogrel Clopidogrel Bisulfate Brand 18 $314

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$151,177

Medicare's payments for the services billed

Medicare patients

305

Average age 76

Services billed

1,602

124 women, 181 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 61%
Diabetes 55%
Chronic kidney disease 48%
Arthritis 45%
Heart failure 31%
COPD 29%
Atrial fibrillation 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

162 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record